ICICI Securities is bullish on Cohance Lifesciences recommended buy rating on the stock with a target price of Rs 1365 in its research report dated May 29, 2025.

Buy Suven Pharmaceuticals; target of Rs 1400: ICICI Securities

ICICI Securities is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 1400 in its research report dated March 25, 2025.

Sell Suven Pharmaceuticals; target of Rs 571: Geojit

Geojit is bearish on Suven Pharmaceuticals has recommended sell rating on the stock with a target price of Rs 571 in its research report dated February 29, 2024.

Buy Suven Pharmaceuticals; target of Rs 530: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 530 in its research report dated November 09, 2022.

Hold Suven Pharmaceuticals: target of Rs 530: ICICI Direct

ICICI Direct recommended hold rating on Suven Pharmaceuticals with a target price of Rs 530 in its research report dated August 09, 2022.

Hold Suven Pharmaceuticals; target of Rs 555: ICICI Direct

ICICI Direct recommended hold rating on Suven Pharmaceuticals with a target price of Rs 555 in its research report dated May 10, 2022.

Suven Pharma: Steady cash flow conversion opportunity merits attention

Suven Pharma remains conservative in its outlook and provides visibility for the next six months. It is confident of executing Q3 sales run rate for the next two quarters

Buy Suven Pharmaceuticals; target of Rs 650: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 650 in its research report dated August 16, 2021.

Suven Pharma: Normalisation of margins adds to comfort

There is an emerging preference for full-service CDMOs. This puts players like Suven in a better spot as it tries to capture the whole of the value chain

Weekly Tactical Pick – Suven Pharma

Technical prowess and healthy balance sheet make Suven Pharma a strong thematic play

Buy Suven Pharmaceuticals; target of Rs 560: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 560 in its research report dated June 09, 2021.

CDMO leader ready to straddle entire pharma value chain

Except phosgenation and fluorination, Suven Pharma is capable of handling every other chemistry. This adds to the scope for contract engagements in speciality chemicals and clinical development for pharma

Buy Suven Pharmaceuticals; target of Rs 375: Anand Rathi

Anand Rathi is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 375 in its research report dated October 31, 2020.

Buy Suven Pharmaceuticals; target of Rs 400: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 400 in its research report dated October 31, 2020.

Buy Suven Pharmaceuticals; target of Rs 462: Dolat Capital Market

Dolat Capital Market is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 462 in its research report dated October 31, 2020.

Buy Suven Pharmaceuticals target of Rs 770: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 770 in its research report dated August 19, 2020.

Buy Suven Pharmaceuticals; target of Rs 760: Anand Rathi

Anand Rathi is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 760 in its research report dated August 18, 2020.

Buy Suven Pharmaceuticals; target of Rs 587: Geojit

Geojit recommended is bullish on Suven Pharmaceuticals recommended buy rating on the stock with a target price of Rs 587 in its research report dated July 02, 2020.

Buy Suven Pharmaceuticals; target of Rs 690: ICICI Direct

ICICI Direct is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 690 in its research report dated June 23, 2020.

Buy Suven Pharmaceuticals; target of Rs 522: Anand Rathi

Anand Rathi is bullish on Suven Pharmaceuticals has recommended buy rating on the stock with a target price of Rs 522 in its research report dated June 20, 2020.